C12N 2501/2307
Interleukin-7
Official title: Interleukin-7 (IL-7)
C12N2501/2307 (Interleukin-7) appears on 202 US grants and 622 published applications in this corpus.
Search patents in C12N- Granted patents
- 202
- Published applications
- 622
- Assignees
- 305
- Inventors
- 1,321
- Latest grant
- 1 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2007 | 0 | 1 |
| 2008 | 0 | 1 |
| 2009 | 0 | 0 |
| 2010 | 0 | 1 |
| 2011 | 1 | 4 |
| 2012 | 3 | 6 |
| 2013 | 0 | 8 |
| 2014 | 2 | 10 |
| 2015 | 7 | 13 |
| 2016 | 5 | 10 |
| 2017 | 7 | 25 |
| 2018 | 7 | 27 |
| 2019 | 8 | 37 |
| 2020 | 19 | 35 |
| 2021 | 19 | 77 |
| 2022 | 16 | 85 |
| 2023 | 24 | 76 |
| 2024 | 30 | 69 |
| 2025 | 36 | 92 |
| 2026 | 18 | 45 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Media and methods for differentiating natural killer cells1 Sep 2026US 12,723,233 B2Stemcell Technologies Canada Inc.
- Methods for directed differentiation of pluripotent stem cells to HLA homozygous immune cells25 Aug 2026US 12,716,058 B2FUJIFILM Cellular Dynamics, Inc.
- Process for producing donor-batched cells expressing a recombinant receptor11 Aug 2026US 12,703,733 B2Juno Therapeutics, Inc.
- Long lived T cells for treating HIV infection4 Aug 2026US 12,698,318 B2Case Western Reserve University
- Antigen presenting T cells, sensitized, manufactured T cells and methods of treatment using the same14 Jul 2026US 12,680,074 B2Rapa Therapeutics, LLC
- Enrichment and expansion of chimeric antigen receptor t cells using antigen-presenting biomaterials1 Oct 2026US 2026/0297520 A1The Regents of the University of California
- Media and methods for differentiating t cells from hematopoietic stem cells17 Sep 2026US 2026/0272984 A1The Regents of the University of California
- Cell treatment product preparation process and use thereof10 Sep 2026US 2026/0265692 A1Chongqing Precision Biotech Company Limited
- T-cells comprising chimeric antigen receptors and compositions thereof for treatment of cancer20 Aug 2026US 2026/0241001 A1King Faisal Specialist Hospital & Research Centre
- Method for regulating degree of cell differentiation30 Jul 2026US 2026/0218131 A1National University Corporation Chiba University
Most cited
By later US patents
- Remnant tumor infiltrating lymphocytes and methods of preparing and using the same27US 11,220,670 B2Iovance Biotherapeutics, Inc. · 2022
- Remnant tumor infiltrating lymphocytes and methods of preparing and using the same27US 11,293,009 B2Iovance Biotherapeutics, Inc. · 2022
- Remnant tumor infiltrating lymphocytes and methods of preparing and using the same26US 11,401,507 B2Iovance Biotherapeutics, Inc. · 2022
- Methods of using tumor infiltrating lymphocytes in double-refractory melanoma26US 11,433,097 B2Iovance Biotherapeutics, Inc. · 2022
- Methods of using tumor infiltrating lymphocytes in double-refractory melanoma24US 11,819,517 B2Iovance Biotherapeutics, Inc. · 2023